article thumbnail

Um, about that diabetes drug that helped patients lose weight

World of DTC Marketing

Wegovy’s most common side effects were gastrointestinal problems, including nausea, diarrhea, and vomiting, which 80% of patients reported, according to USA Today. Novo’s PR department did a great job and most articles about the drug did talk about the side effects but how many people really read that deep?

article thumbnail

A scientific approach to irrational consumer choices

World of DTC Marketing

A review, authored by researchers at RTI International and the US Food and Drug Administration (FDA), looked at 38 studies published between 1982 and 2017 that examined outcomes reported by patients, prescribers, or both regarding their experience with DTC advertising in the US and New Zealand.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

But along with strong efficacy come some considerable risks and costs: cytokine release syndrome (CRS), where a patient’s immune system becomes dangerously over-stimulated, and neurotoxicity are potential side effects that need to be managed. Side effects and cost implications.

article thumbnail

Tackling the complex development landscape of pain medicines

European Pharmaceutical Review

The current medications (opioid and non-opioid) often force the patients to make an unfortunate choice between efficacy and debilitating side effects, leading to a cycling through multiple different therapies and suboptimal treatment response. 2017; 6(S1):1–3. Neuropathic pain: The scope of the problem. Pain and Therapy.

article thumbnail

Briumvi may struggle to make headway in crowded multiple sclerosis market

Pharmaceutical Technology

Briumvi is the third approved injectable MS treatment directed against CD20 antigen expressed on B cells, with the other therapies being Kesimpta (ofatumumab, approved in 2020) and Ocrevus (ocrelizumab, approved in 2017). All three treatments are monoclonal antibodies. Some 48% of patients on Briumvi also suffered with infusion reactions.

article thumbnail

Newron says pivotal treatment-resistant schizophrenia trial is a go

pharmaphorum

Side-effect data from the open-label studies was also encouraging, helping to downplay concerns abut evenamide’s cardiovascular and central nervous system safety that emerged in 2019. ” The new data could accelerate partnering efforts of the drug this year.

article thumbnail

Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis

pharmaphorum

Minor side effects to long-term maintenance balance. Any clinical study seeks to achieve maximum results efficacy with minimal occurrence of side effects. However, side effects do happen. Regarding both common cold and headache, they are as well among the side effects reported for similar drugs.